Home＞BUSINESS
-
Takeda, Wave Ink Antisense Pact for Neurological Diseases
February 22.2018 -
-
Bristol-Myers Japan Taps Ex-AZ Exec Hashigami as Development Chief
February 21.2018 -
Taniuchi Appointed as Santen President and COO
February 21.2018 -
Aducanumab Trial Tweak “Common Decision” to Boost Statistical Confidence: Biogen CEO
February 21.2018 -
Seikagaku to Run Add’l PIII for Lumbar Disc Herniation Drug in US
February 20.2018 -
Dovobet Gel Wins Japan Approval: LEO/Kyowa Kirin
February 20.2018 -
Takeda’s Specialty Biz Unit Most Likely to Handle GI Meds, Entyvio Launch Apparently Eyed
February 20.2018
- No Dialogue at New “Public-Private Dialogue” Confab with Limited Time, JPMA Says(Apr.20)
- Expert Cautions against Hasty Discussions on Cost Effective Assessments(Apr.20)
- Label Revision Ordered for Keytruda with Sclerosing Cholangitis as ADR(Apr.20)
- Takeda in Talks with Shire after 3 Buyout Proposals Rejected(Apr.20)
- Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers(Apr.20)
